N/A N=258 Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 EPIONE Guided Lung Evaluation
Lung Cancer
Primary: Feasibility of the Device — 26 Number of targets reached
N/A N=23 iNod System Human Feasibility Assessment
Solitary Pulmonary Nodule · Biopsy, Fine-Needle
Primary: Acquisition of Adequate Specimens of Targeted Lung Lesions — 9 Participants
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
N/A N=105 Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling
Lung Cancer
Primary: Safety Measurement — 0; 0; 0; 0 Adverse events
Phase 2 N=117 Navelbine And Radiotherapy in Locally Advanced Lung Cancer
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Phase 2 N=25 Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions
Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1 Participants
N/A N=1,200 Patient Navigation for Lung Screening at MGH Community Health Centers
Lung Cancer
Primary: Chest CT Completion — 124; 138 Participants
Phase 2 N=124 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Phase 3 N=291 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
Nonsmall Cell Lung Cancer · NSCLC
Primary: Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)…
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 2 N=181 Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
Non-Small-Cell Lung Carcinoma
Primary: The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) — 2; 0…
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Phase 2 N=68 Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NSCLC Non-small Cell Lung Cancer
Primary: Event-free Survival (EFS) Rate — 73.4 percentage of participants
N/A N=30 InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology
Lung Cancer
Primary: The Ability of BioSpy System to Acquire Electrophysiological Measurements in the Relevant Tissues During Bronchoscopic Biopsy. — 26 Participants
N/A N=1,864 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Screen Success Rate — 655 Participants
Phase 2 N=89 Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Lung Cancer · Lung Metastases
Primary: Clinically Significant Events (CSE) — 0.449 Proportion of subjects — p=<.0001
Phase 3 N=112 ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Lung Neoplasms · Lung Cancer
Primary: Clinically Significant Events (CSE) — .530 proportion of participants
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 3 N=713 Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) as Assessed by Central Independent Review — 4.4; 3.6 months — p=0.0435
Phase 2 N=52 Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
Lung Cancer
Primary: Disease Response - Radiographic — 1; 16 participants
Phase 3 N=53,454 National Lung Screening Trial (NLST) Screening
Lung Cancer
Primary: Lung Cancer Deaths — 356; 443 Participants — p=0.004
Phase 2 N=21 BIO 300 Non-Small Cell Lung Cancer Study
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity — 0; 0; 0; 6 Participants
Phase 2 N=100 OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Lung Neoplasms · Lung Cancer
Primary: Sensitivity or True Positive Rate (TPR) — 0.854 proportion of lesions
Phase 2 N=98 Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules
Current Smoker · Former Smoker · Multiple Pulmonary Nodules
Primary: Change in the Sum of Longest Diameters of Baseline Target Nodules (Person-specific Analysis) — 0.3; -0.12 millimeter (mm)
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 1 N=16 A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0 Participants
N/A N=207 Autologous Stem Cell Treatment for Chronic Lung Disease Study
COPD · Interstitial Lung Disease
Primary: Change in FEV1 From Baseline Among COPD Patients — 12.8 percentage of change in FEV1